Literature DB >> 30515665

[Real-life study of psoriasiform side effects from tumor necrosis factor antagonists in inflammatory bowel diseases].

Hans-Hartmut Peter1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30515665     DOI： 10.1007/s00393-018-0572-9

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  5 in total

1.  Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.

Authors:  Jean David Cohen; Irina Bournerias; Valérie Buffard; Agnès Paufler; Xavier Chevalier; Martine Bagot; Pascal Claudepierre
Journal:  J Rheumatol       Date:  2006-10-01       Impact factor: 4.666

Review 2.  Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action.

Authors:  Angelique N Collamer; Karen T Guerrero; Jeffery S Henning; Daniel F Battafarano
Journal:  Arthritis Rheum       Date:  2008-07-15

3.  Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study.

Authors:  Damien Fouache; Vincent Goëb; Nathalie Massy-Guillemant; Gilles Avenel; Helene Bacquet-Deschryver; Macha Kozyreff-Meurice; Jean-François Ménard; Marc Muraine; Guillaume Savoye; Xavier Le Loët; Christine Tharasse; Olivier Vittecoq
Journal:  Rheumatology (Oxford)       Date:  2009-04-24       Impact factor: 7.580

4.  Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study.

Authors:  J M Bae; H H Lee; B-I Lee; K-M Lee; S H Eun; M-L Cho; J S Kim; J M Park; Y-S Cho; I S Lee; S W Kim; H Choi; M-G Choi
Journal:  Aliment Pharmacol Ther       Date:  2018-06-05       Impact factor: 8.171

5.  Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system.

Authors:  Kevin E Kip; Jason M Swoger; Lisa M Grandinetti; Arthur M Barrie; Julia B Greer; Miguel D Regueiro
Journal:  Inflamm Bowel Dis       Date:  2013-05       Impact factor: 5.325
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.